Weight-Loss Drugs Are Everywhere. How the GLP-1 Copycats Took Over. -- Barron's
Express News | Novo Nordisk A/S has committed to invest 0.1582 billion US dollars in a insulin factory in Brazil.
Novo Nordisk's Options: A Look at What the Big Money Is Thinking
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
What End of Eli Lilly's Weight-loss Drug Shortage Means for the Competition
Eli Lilly's Mounjaro, Zepbound Removed From FDA's Shortage List
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher Plant Making Astra/ Sanofi RSV Drug Reportedly Breached FDA Rules
Top Midday Stories: Levi Strauss Shares Fall After Sales Miss, Strategic Review of Dockers Brand Announcement; Tesla's Model 3 Standard Range Variant Unavailable for Order in US
Novo Nordisk Currently Down Six Consecutive Days, on Pace for Longest Losing Streak Since September 2022 -- Data Talk
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk
U.S. Tweaks 2025 Medicare Price Negotiation Process
Hims & Hers Health Shares Fall After Weight-Loss Drug Shortage Ends
Eli Lilly's Weight-loss Drug No Longer in Shortage, FDA Says
FDA announced eli lilly and co's weight loss miracle drug is no longer in short supply, the generic drug market may be affected.
Shortages of eli lilly and co's popular weight loss and diabetes drugs Zepbound and Mounjaro have been resolved, which may impact generic products prevalent in the market.
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over. -- Barrons.com
Express News | Novo Nordisk : Jefferies Raises Target Price to $85.5 From $84